Delcath Systems Yönetim

Yönetim kriter kontrolleri 2/4

Delcath Systems CEO'su Gerard Michel, Oct2020 tarihinde atandı, in görev süresi 4.17 yıldır. in toplam yıllık tazminatı $ 2.52M olup, şirket hissesi ve opsiyonları dahil olmak üzere 21.3% maaş ve 78.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1% ine doğrudan sahiptir ve bu hisseler € 3.61M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 4.6 yıldır.

Anahtar bilgiler

Gerard Michel

İcra Kurulu Başkanı

US$2.5m

Toplam tazminat

CEO maaş yüzdesi	21.3%
CEO görev süresi	4.2yrs
CEO sahipliği	1.0%
Yönetim ortalama görev süresi	2.2yrs
Yönetim Kurulu ortalama görev süresi	4.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Gerard Michel'un ücretlendirmesi Delcath Systems'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$34m
Jun 30 2024	n/a	n/a	-US$56m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$3m	US$538k	-US$48m
Sep 30 2023	n/a	n/a	-US$45m
Jun 30 2023	n/a	n/a	-US$34m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$1m	US$521k	-US$37m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$32m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$2m	US$475k	-US$26m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$6m	US$113k	-US$24m

Tazminat ve Piyasa: Gerard 'nin toplam tazminatı ($USD 2.52M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.02M ).

Tazminat ve Kazançlar: Gerard şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Gerard Michel (61 yo)

4.2yrs

Görev süresi

US$2,520,314

Tazminat

Mr. Gerard J. Michel, MS, MBA, serves as Chief Executive Officer and Director at Delcath Systems Inc since October 1, 2020. He had been Chief Financial Officer and Vice President of Corporate Development a...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gerard Michel	CEO & Director	4.2yrs	US$2.52m	1.0% € 3.6m
Sandra Pennell	Senior VP of Finance and Principal Financial & Accounting Officer	1.5yrs	Veri yok	0.19% € 690.5k
Martha Rook	Chief Operating Officer	less than a year	Veri yok	Veri yok
David Hoffman	General Counsel	2.9yrs	Veri yok	0.23% € 840.6k
Johnny John	Senior Vice President of Clinical Operations & Medical Affairs	3.9yrs	US$737.50k	Veri yok
Vojislav Vukovic	Chief Medical Officer	1.5yrs	Veri yok	0.40% € 1.4m

2.2yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: DV3R 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gerard Michel	CEO & Director	4.2yrs	US$2.52m	1.0% € 3.6m
Elizabeth Czerepak	Independent Director	4.8yrs	US$188.51k	0% € 0
Steven Salamon	Independent Director	4.6yrs	US$183.96k	0.26% € 929.6k
John Sylvester	Independent Chairman	5.4yrs	US$204.88k	0.033% € 119.3k
Gilad Aharon	Independent Director	4.6yrs	US$172.96k	0.097% € 349.3k
Bridget Martell	Director	less than a year	Veri yok	Veri yok

4.6yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DV3R 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.6 yıldır).

Delcath Systems Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Executive Changes

CEO & Director recently bought €93k worth of stock

Chief Medical Officer recently bought €137k worth of stock

Recent updates

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Colorectal Cancer

Third quarter 2024 earnings released: EPS: US$0.065 (vs US$1.14 loss in 3Q 2023)

Forecast breakeven date moved forward to 2025

Forecast breakeven date moved forward to 2025

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Second quarter 2024 earnings released: US$0.48 loss per share (vs US$0.58 loss in 2Q 2023)

Delcath Systems Regains Compliance with the Audit Committee Composition Requirements

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors

New major risk - Financial position

New minor risk - Financial position

Delcath Systems, Inc. to Report Q1, 2024 Results on May 14, 2024

Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$2.94 loss per share (vs US$4.12 loss in FY 2022)

Delcath Systems, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

Delcath Systems, Inc. Announces Executive Changes

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit™

No longer forecast to breakeven

CEO & Director recently bought €93k worth of stock

Chief Medical Officer recently bought €137k worth of stock

Third quarter 2023 earnings released: US$1.14 loss per share (vs US$0.92 loss in 3Q 2022)

Insufficient new directors

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.58 loss per share (vs US$1.18 loss in 2Q 2022)

Delcath Systems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Delcath Systems, Inc. Appoints Sandra Pennell as Senior Vice President of Finance

Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023

Full year 2022 earnings released: US$4.12 loss per share (vs US$3.59 loss in FY 2021)

Delcath Systems, Inc. Announces Board Changes

Delcath Systems, Inc. Announces New Drug Application Resubmission for HEPZATO Kit

Delcath Systems Announces Updated Results from Chopin Phase 1B Trial Published in Cardiovascular and Interventional Radiology

Forecast to breakeven in 2025

Independent Director recently bought €52k worth of stock

Delcath Systems, Inc. announced that it has received $6.201779 million in funding

Delcath Systems, Inc. Announces Results of Single Center Study on Delcath's CHEMOSAT Hepatic Delivery System in the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Third quarter 2022 earnings released: US$0.92 loss per share (vs US$0.94 loss in 3Q 2021)

Delcath Systems, Inc. Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$1.18 loss per share (vs US$0.96 loss in 2Q 2021)

Results of A Multicenter Study on Delcath's Chemosat Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Delcath Systems, Inc. announced that it has received $4.999998 million in funding

CEO & Director recently bought €245k worth of stock

Delcath Systems, Inc. announced that it expects to receive $5.000038 million in funding

First quarter 2022 earnings released: US$1.00 loss per share (vs US$1.04 loss in 1Q 2021)

High number of new and inexperienced directors

Delcath Systems, Inc., Annual General Meeting, May 04, 2022

Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT

Delcath Systems, Inc. Appoints Anthony Dias as its New Vice President of Finance

Delcath Systems, Inc. Announces Result of Single Center Study on Delcath’s CHEMOSAT Hepatic Delivery System Published in Melanoma Research

CEO & Director recently bought €177k worth of stock

Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$1.16 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.96 loss per share (vs US$1.91 loss in 2Q 2020)

Delcath Systems, Inc. announced that it expects to receive $20 million in funding from Avenue Capital Group

CEO & Director recently bought €125k worth of stock

Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$1.04 loss per share (vs US$108 loss in 1Q 2020)

Full year 2020 earnings released: US$8.36 loss per share (vs US$343 loss in FY 2019)

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş